The Realities of “Right to Try”

In May 2018, President Donald Trump signed into law the Trickett Wendler, Frank Mongiello, Jordan McLinn and Matthew Bellina Right to Try Act of 2017.1 The law amends the Federal Food, Drug, and Cosmetic...

Online Exclusives

MSKCC Researchers Correct Financial Disclosures

After reports from ProPublica and The New York Times revealed that scientists from Memorial Sloan Kettering Cancer Center (MSKCC) failed to disclose financial relationships...

Congress Passes Bills Banning Gag Clauses

Congress has passed two bills to ban “gag clauses” in contracts between pharmacies and insurance companies or pharmacy benefit managers (PBMs). The legislation, supported...

News

From the Blood Journals

WIB_icon

Examining Hospice Use Among Transfusion-Dependent Patients With Leukemia

Since 2001, more patients with leukemia are receiving hospice services, which has been associated with improved quality of life, according to an analysis published...
WIB_icon

Mapping Silent Cerebral Infarcts in Children With Sickle Cell Anemia

Children with sickle cell anemia (SCA) are at risk of developing cerebral ischemia, including a high prevalence of silent cerebral infarcts (SCI), which can...

Multimedia

Pulling Back the Curtain: Vip Viprakasit, MD, DPhil

In more from our interview with Dr. Viprakasit, he speaks about the advantages of working in a limited-resource setting and the importance of international...

Let’s Get Cooking: Jonathan Hoggatt, PhD

In more from our interview with Dr. Hoggatt, he talks about the chocolate chip cookie experiment that started his obsession with cooking.

Pulling Back the Curtain: Richard W. Childs, MD

Hear more from our interview with Dr. Childs, where he talks about his inventive career in medicine and the best and worst parts of his...

LentiGlobin Gene Therapy Possibly Safe for Severe Sickle Cell Disease

Interim data from a phase I study of LentiGlobin BB305 in patients with severe sickle cell disease (SCD) suggest that the gene therapy was...

On Location

From ASH Meeting on Hematologic Malignancies: Treating Patients With AML With Mutations and Minimal Residual Disease

During their presentations, MHM speakers will be asking the audience how they would respond to...

From ASH Meeting on Hematologic Malignancies: Treating “Problematic” Cases of Polycythemia Vera

During their presentations, MHM speakers will be asking the audience how they would respond to...

From ASH Meeting on Hematologic Malignancies: Treating a Young Patient With Newly Diagnosed ALL

During their presentations, MHM speakers will be asking the audience how they would respond to...

Researchers Define Long-Term Outcomes of Cancer-Associated Thrombosis

Patients diagnosed with cancer-associated thrombosis (CAT) remain at a high risk for recurrent venous thromboembolism...

Romiplostim Helps Patients With Glioblastoma and Thrombocytopenia Stay on Treatment

Temozolomide (TMZ) is part of the standard treatment for patients with glioblastoma, but the drug...

APR-246 Plus Azacitidine Is Associated With High Response Rates in MDS and AML

In a small phase IB/II trial presented at the 23rd Congress of the European Hematology...

Latest Headlines

Advertisement

ASH Directions

Announcing the 2018 Honorific and Mentor Award Recipients, and more

Announcing the 2018 Honorific and Mentor Award Recipients!  ASH will recognize these distinguished leaders in hematology through awards and special lectures at the 60th ASH...

Start Planning Now for the 60th ASH Annual Meeting and Exposition, and more

Start Planning Now for the 60th ASH Annual Meeting and Exposition  The preliminary program for the 2018 ASH annual meeting is now available online. The...

Sign up for our
eNewsletter!

Jonas Sokolof Named Director of NYU Langone’s New Rehab Program for Cancer Survivors, and...

Jonas Sokolof Appointed Director of NYU Langone’s New Rehabilitation Program for Cancer Survivors  NYU Langone’s Rusk Rehabilitation has opened the Division of Oncological Rehabilitation, launching...

NIH Awards $24 Million to UT Health San Antonio, and more

Remembering Michael C. Lill (1959-2018)  Michael C. Lill, MD, passed away on June 19, 2018, after a long battle with cancer. Dr. Lill was born...

Fred Hutch Scientists Receive $20 Million for Leukemia Projects, and more

Remembering Alan Rabson (1926 – 2018)Alan Rabson, MD, a long-time leader at the National Cancer Institute (NCI), passed away on July 4, 2018, at...

The Realities of “Right to Try”

In May 2018, President Donald Trump signed into law the Trickett Wendler, Frank Mongiello, Jordan McLinn and Matthew Bellina Right to Try Act of...

Breakthroughs in Gene Therapy for Hemophilia

Gene therapy for hemophilia is here – and it’s working. The field is advancing at a steady clip: Results from recent trials of this...

The Code of Misconduct

Scientific misconduct is more than falsification, fabrication, and plagiarism – and harder to identify.  In 1998, Andrew Wakefield, MD, and co-authors investigated a cohort of...